Tumor-infiltrating lymphocytes (TIL) are a predictive biomarker for response to chemotherapy and immunotherapy, while phosphoinositide 3-kinase (PIK3CA) mutations predict response to targeted therapy [2]. Here, PIK3CA is linked to neoplasm.